Diamedica Therapeutics (DMAC) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Diamedica Therapeutics Inc. has filed a Form 8-K with the SEC, detailing a current report that could impact its stock, traded under the symbol DMAC on The Nasdaq Stock Market LLC. The report, dated May 8, 2024, pertains to the company, headquartered in Minneapolis, Minnesota, which is not classified as an emerging growth company.
For further insights into DMAC stock, check out TipRanks’ Stock Analysis page.
